- Home
- HPK vs LXRX Comparison
HPK vs LXRX Comparison
Compare HPK & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HPK | LXRX |
|---|---|---|
| Founded | 2019 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 866.8M | 990.6M |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | HPK | LXRX |
|---|---|---|
| Price | $7.45 | $2.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | $4.15 |
| AVG Volume (30 Days) | 471.9K | ★ 2.9M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $863,359,000.00 | $49,803,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $3.85 | $1.03 |
| 52 Week High | $9.13 | $2.68 |
Technical Indicators
Market Signals| Indicator | HPK | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.22 | 50.32 |
| Support Level | $7.23 | $1.96 |
| Resistance Level | $8.32 | $2.50 |
| Average True Range (ATR) | 0.55 | 0.16 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 39.01 | 66.07 |
Price Performance
Historical ComparisonAbout HPK HighPeak Energy Inc.
HighPeak Energy Inc is an independent crude oil and natural gas exploration and production company that explores for, develops and produces crude oil, NGL, and natural gas prominently in Howard County of the Midland Basin. The company operates in a single segment, which is crude oil and natural gas development, exploration, and production in the U.S. The majority of the company's revenue is derived from the Crude oil sales.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.